Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference
Cabaletta Bio (NASDAQ: CABA), a clinical-stage biotech company developing curative targeted cell therapies for autoimmune diseases, announced its participation in the upcoming Jefferies Global Healthcare Conference. The company will engage in a fireside chat on June 4, 2025, at 11:05 a.m. ET in New York. Investors and interested parties can access a live webcast of the presentation through Cabaletta's website, with replays available for 30 days following the event.
Cabaletta Bio (NASDAQ: CABA), un'azienda biotecnologica in fase clinica che sviluppa terapie cellulari mirate e curative per le malattie autoimmuni, ha annunciato la sua partecipazione alla prossima Jefferies Global Healthcare Conference. L'azienda parteciper脿 a una discussione informale il 4 giugno 2025, alle 11:05 ET a New York. Investitori e interessati potranno seguire la presentazione in diretta streaming sul sito web di Cabaletta, con la possibilit脿 di rivedere la registrazione per 30 giorni dopo l'evento.
Cabaletta Bio (NASDAQ: CABA), una empresa biotecnol贸gica en etapa cl铆nica que desarrolla terapias celulares dirigidas y curativas para enfermedades autoinmunes, anunci贸 su participaci贸n en la pr贸xima Jefferies Global Healthcare Conference. La compa帽铆a participar谩 en una charla informal el 4 de junio de 2025, a las 11:05 a.m. ET en Nueva York. Los inversores e interesados podr谩n acceder a una transmisi贸n en vivo de la presentaci贸n a trav茅s del sitio web de Cabaletta, con repeticiones disponibles durante 30 d铆as despu茅s del evento.
Cabaletta Bio (NASDAQ: CABA)電� 鞛愱皜氅挫棴 歆堩櫂鞚� 旃橂頃橂姅 響滌爜 靹疙彫 旃橂鞝滊ゼ 臧滊皽頃橂姅 鞛勳儊 雼硠鞚� 氚旍澊鞓ろ厤 旮办梾鞙茧, 雼り皜鞓る姅 Jefferies 旮�搿滊矊 項姢旒�鞏� 旎嵓霟办姢鞐� 彀胳棳頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 須岇偓電� 2025雲� 6鞗� 4鞚� 鞓れ爠 11鞁� 05攵�(霃欕秬鞁滉皠) 雺挫殨鞐愳劀 歆勴枆霅橂姅 韺岇澊鞏挫偓鞚措摐 毂勴寘鞐� 彀胳棳頃� 鞓堨爼鞛呺媹雼�. 韴瀽鞛� 氚� 甏�鞁� 鞛堧姅 攵勲摛鞚� Cabaletta 鞗轨偓鞚错姼毳� 韱淀暣 霛检澊敫� 鞗轨簮鞀ろ姼毳� 鞁滌箔頃� 靾� 鞛堨溂氅�, 頄夓偓 頉� 30鞚缄皠 雼れ嫓氤搓赴 靹滊箘鞀る弰 鞝滉车霅╇媹雼�.
Cabaletta Bio (NASDAQ : CABA), une entreprise biotechnologique en phase clinique d茅veloppant des th茅rapies cellulaires cibl茅es et curatives pour les maladies auto-immunes, a annonc茅 sa participation 脿 la prochaine Jefferies Global Healthcare Conference. La soci茅t茅 participera 脿 une discussion informelle le 4 juin 2025 脿 11h05 (heure de l'Est) 脿 New York. Les investisseurs et parties int茅ress茅es pourront acc茅der 脿 une diffusion en direct de la pr茅sentation via le site web de Cabaletta, avec des rediffusions disponibles pendant 30 jours apr猫s l'茅v茅nement.
Cabaletta Bio (NASDAQ: CABA), ein biotechnologisches Unternehmen in der klinischen Phase, das kurative, zielgerichtete Zelltherapien f眉r Autoimmunerkrankungen entwickelt, gab seine Teilnahme an der bevorstehenden Jefferies Global Healthcare Conference bekannt. Das Unternehmen wird am 4. Juni 2025 um 11:05 Uhr ET in New York an einem Fireside-Chat teilnehmen. Investoren und Interessierte k枚nnen die Pr盲sentation live 眉ber die Website von Cabaletta verfolgen, mit Wiedergaben, die bis zu 30 Tage nach der Veranstaltung verf眉gbar sind.
- None.
- None.
PHILADELPHIA, May 29, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 11:05 a.m. ET in New York, NY.
A live webcast of the presentation will be available on the News and Events section of the Company鈥檚 website at聽. Replays will be available on the website for 30 days.
About Cabaletta Bio
Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases. The CABA鈩� platform encompasses two complementary strategies which aim to advance the discovery and development of engineered T cell therapies with the potential to become deep and durable, perhaps curative, treatments for a broad range of autoimmune diseases. The lead CARTA (Chimeric Antigen Receptor T cells for Autoimmunity) strategy is prioritizing the development of rese-cel, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy. Rese-cel is currently being evaluated in the RESET鈩� (REstoring SElf-Tolerance) clinical development program spanning multiple therapeutic areas, including rheumatology, neurology and dermatology. Cabaletta Bio鈥檚 headquarters and labs are located in Philadelphia, PA. For more information, please visit聽聽and connect with us on LinkedIn.
Contacts:
Anup Marda
Chief Financial Officer
FAQ
When is Cabaletta Bio (CABA) presenting at the Jefferies Healthcare Conference 2025?
How can I watch Cabaletta Bio's (CABA) presentation at the Jefferies Conference?
What type of therapies is Cabaletta Bio (CABA) developing?
What is Cabaletta Bio's (CABA) current development stage?
